Treatment of Patients with Systemic-onset Juvenile Idiopathic Arthritis with Tacrolimus

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2019 Feb 21

PMID 30783487

Citations 8

Authors

Dongdong Wang

Xiao Chen

Zhiping Li

Affiliations

Soon will be listed here.

Abstract

Previously, few studies have reported treatment with tacrolimus (TAC) for patients with systemic-onset juvenile idiopathic arthritis (SOJIA). The aim of the current study was to investigate the effect of TAC on patients with SOJIA. Data were collected from the beginning of treatment with TAC to the 12-month endpoint, which was defined as the last follow-up. Clinical characteristics included sex, age, duration of the disease, TAC dose, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), hemoglobin (Hb), platelet (PLT) and white blood cell (WB) levels, prednisolone (PDN) dose and interleukin-6 (IL-6) expression. The baseline characteristics of the patients were: ESR, 67.8±18.7 mm/h; CRP, 128.0±38.9 mg/l; Hb, 108.7±13.7 g/l; PLT, 416.8±90.1×10/l; WB, 26.0±10.2×10/l; PDN dose, 49.0±17.1 mg/day. Following 12 months of treatment with TAC, ESR, CRP, PLT and WB levels, and the dose of PDN required for the treatment of patients with SOIJA were all decreased compared with the baseline values. No serious adverse reactions were reported. Therefore, TAC could be an effective treatment for SOJIA.

Citing Articles

CXCR2 Activated JAK3/STAT3 Signaling Pathway Exacerbating Hepatotoxicity Associated with Tacrolimus.

Chen X, Hu K, Zhang Y, He S, Wang D Drug Des Devel Ther. 2025; 18:6331-6344.

PMID: 39749191 PMC: 11693940. DOI: 10.2147/DDDT.S496195.

Treatment of systemic juvenile idiopathic arthritis.

Hinze C, Foell D, Kessel C Nat Rev Rheumatol. 2023; 19(12):778-789.

PMID: 37923864 DOI: 10.1038/s41584-023-01042-z.

Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.

Ambler W, Nanda K, Onel K, Shenoi S Ann Med. 2022; 54(1):1839-1850.

PMID: 35786149 PMC: 9258439. DOI: 10.1080/07853890.2022.2095431.

Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis.

Zhang M, Dai R, Zhao Q, Zhou L, An Y, Tang X Front Mol Biosci. 2021; 8:681526.

PMID: 34336925 PMC: 8316978. DOI: 10.3389/fmolb.2021.681526.

Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation.

Chen X, Wang D, Xu H, Li Z Transl Pediatr. 2020; 9(5):576-586.

PMID: 33209719 PMC: 7658763. DOI: 10.21037/tp-20-84.

References

Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T . Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002; 17(4):655-62. DOI: 10.1093/ndt/17.4.655. View

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M . Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003; 48(4):1093-101. DOI: 10.1002/art.10885. View

Yokota S . Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol. 2003; 15(5):581-6. DOI: 10.1097/00002281-200309000-00010. View

Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M . Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004; 31(2):243-51. View

Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I . Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005; 32(5):935-42. View

Mok C, Tong K, To C, Siu Y, Au T . Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005; 68(2):813-7. DOI: 10.1111/j.1523-1755.2005.00461.x. View

Kawai S, Yamamoto K . Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford). 2005; 45(4):441-4. DOI: 10.1093/rheumatology/kei172. View

Tanaka H, Tsugawa K, Nakahata T, Suzuki K, Ito E . Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis. Clin Rheumatol. 2006; 26(6):1014-6. DOI: 10.1007/s10067-006-0256-8. View

Suzuki K, Tsugawa K, Tanaka H . Tacrolimus for the treatment of focal segmental glomerulosclerosis resistant to cyclosporine A. Pediatr Nephrol. 2006; 21(12):1913-4. DOI: 10.1007/s00467-006-0198-z. View

10.

Tanaka H, Tsugawa K, Suzuki K, Oki E, Nonaka K, Kimura S . Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 2006; 166(10):1053-5. DOI: 10.1007/s00431-006-0380-0. View

11.

Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A . Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007; 204(9):2131-44. PMC: 2118700. DOI: 10.1084/jem.20070070. View

12.

De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio G, Martini A . Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34(9):1158-63. DOI: 10.1002/art.1780340912. View

13.

Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C . A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2010; 70(5):747-54. PMC: 3070271. DOI: 10.1136/ard.2010.134254. View

14.

Morgan DeWitt E, Kimura Y, Beukelman T, Nigrovic P, Onel K, Prahalad S . Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012; 64(7):1001-10. PMC: 3368104. DOI: 10.1002/acr.21625. View

15.

Vastert S, de Jager W, Noordman B, Holzinger D, Kuis W, Prakken B . Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014; 66(4):1034-43. DOI: 10.1002/art.38296. View

16.

Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N, Yachie A . Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology (Oxford). 2014; 53(11):2120-2. DOI: 10.1093/rheumatology/keu297. View

17.

Hahn D, Hodson E, Willis N, Craig J . Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; (3):CD001533. PMC: 7025788. DOI: 10.1002/14651858.CD001533.pub5. View

18.

Cimaz R . Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016; 15(9):931-4. DOI: 10.1016/j.autrev.2016.07.004. View

19.

Schulert G, Minoia F, Bohnsack J, Cron R, Hashad S, Kone-Paut I . Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2017; 70(3):409-419. DOI: 10.1002/acr.23277. View